21 October 2024
ECO Animal Health Group plc
("ECO" or the "Company")
EBT Share Purchase
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces it has been notified that the trustees of the ECO Animal Health Group EBT (the "EBT") have completed the following purchases of ordinary shares of 5 pence each in the Company ("Ordinary Shares"). On 14 October 2024, the EBT purchased 25,000 Ordinary Shares at a price of 74.0 pence per Ordinary Share. On 18 October 2024, the EBT purchased 162,928 Ordinary Shares at a price of 77.0 pence per Ordinary Share.
These Ordinary Shares are to be held in the EBT and are intended to be used to satisfy the future vesting of share options granted to employees of the Company. The EBT is a discretionary trust for the benefit of the Company's employees, including the Directors of the Company. The purchase of Ordinary Shares by the EBT has been funded by a gift provided by the Company from its existing cash resources.
Following this transaction, a total of 237,928 Ordinary Shares are held by the EBT, representing approximately 0.35 per cent. of the Company's total voting rights.
-Ends-
For further information please contact:
| |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.